Browse the evidence

Sensitivity analyses showed similar results regarding the association of EPA and DHA levels with cardiovascular outcomes.

The consistency of results across analyses reinforces the conclusion that EPA and DHA levels do not impact cardiovascular outcomes.

Food insecurity is a powerful social determinant of health that impacts health outcomes.

Addressing food insecurity is crucial for improving health outcomes.

Nutrition insecurity is a direct determinant of health.

Practitioners should recognize nutrition insecurity as a critical health factor.

Improvement or remission of diabetes occurred in 68%, hypertension in 61%, and dyslipidemia in 57% of the entire cohort.

Bariatric surgery can lead to significant improvements in obesity-related comorbidities.

The Maintain IT model suggests that centred identity transformation can facilitate successful recruitment of executive function for long-term health behaviour change.

Practitioners may consider focusing on identity transformation strategies to support clients in maintaining health behaviour changes.

The Maintain IT model integrates factors not typically examined together to elucidate processes for behaviour change maintenance.

Practitioners should consider a holistic approach that combines various factors influencing behaviour change.

Betaine and choline concentrations were associated with greater insulin sensitivity.

Increased intake of betaine and choline may enhance insulin sensitivity, suggesting potential dietary recommendations.

Discontinuing GLP-1RA treatment leads to a pooled overall mean weight regain of 2.20 kg in participants taking liraglutide and 9.69 kg in those prescribed semaglutide/tirzepatide.

Practitioners should consider the likelihood of weight regain when discontinuing GLP-1RA therapy.

The proportion of weight regained after discontinuation of GLP-1RA therapy is proportional to the amount originally lost.

Weight loss strategies should account for the likelihood of proportional weight regain after stopping GLP-1RA therapy.

Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions.

Clinicians should inform patients that stopping GLP-1RA may lead to weight regain despite lifestyle efforts.

The DAROC clinical practice guidelines for diabetes care- 2018 include recommendations for diagnostic criteria and treatment goals for various populations.

Practitioners should refer to the DAROC guidelines for comprehensive diabetes care recommendations.

Higher training frequency (2 days per week) may provide a slight benefit in some outcome measurements.

Consider incorporating higher training frequency for potentially better outcomes.

Both training frequencies (1 day/week and 2 days/week) significantly enhance neuromuscular adaptations.

Both training frequencies are effective for improving neuromuscular performance.

More repetitions performed in a set are associated with greater inaccuracy in RIR predictions.

Practitioners should consider the number of repetitions when assessing RIR to improve accuracy.

Lean mass remained stable in some cases, but notable reductions were observed in others, ranging from almost 0% to 40% of total weight reduction.

Clinicians should monitor lean mass changes in patients using semaglutide, as results can vary significantly.

All trial arms had significant reductions in weight and hemoglobin A1c levels from baseline, but no significant differences were found between intervention arms and the control arm.

While all interventions led to weight and A1c reductions, the lack of differences suggests that any intervention may be beneficial.

Endoscopic sleeve gastroplasty (ESG) is more cost-effective than semaglutide over a 5-year time horizon, with an incremental cost-effectiveness ratio (ICER) of -$595,532/QALY.

Practitioners may consider ESG as a more cost-effective option for treating class II obesity compared to semaglutide.

AM833 is a novel nonselective agonist of calcitonin family receptors that has demonstrated efficacy for the treatment of obesity in phase 2 clinical trials.

AM833 may be a promising treatment option for obesity management.

Targeting amylin receptors improves weight control and may act additively with other treatments.

Combining treatments targeting amylin receptors may enhance obesity management strategies.

The high-bar back-squat (HBBS) is characterized by greater knee flexion, lesser hip flexion, a more upright torso, and a deeper squat compared to the low-bar back-squat (LBBS).

Practitioners can use HBBS to emphasize knee flexion and quadriceps engagement.

The low-bar back-squat (LBBS) is characterized by greater hip flexion and a greater forward lean compared to the high-bar back-squat (HBBS).

Practitioners can use LBBS to target hip musculature and posterior chain development.

The high-bar back-squat (HBBS) is associated with greater quadriceps muscle activity, while the low-bar back-squat (LBBS) is associated with greater muscle activity of the erector spinae, adductors, and gluteal muscles.

Practitioners can choose squat variations based on desired muscle engagement.

Remission was greater in younger participants and those with shorter diabetes duration, higher C-peptide levels, higher HOMA %B, and lower insulin usage at baseline.

Younger patients and those with better baseline metabolic health may achieve better outcomes post-surgery.

Controlling for weight lost, diabetes remission remained nearly 4-fold higher after RYGB compared with LAGB.

RYGB may offer superior long-term diabetes remission compared to LAGB, independent of weight loss.